BBOT vs ZTS · rev $7.5M vs P/E 25, rev $2.47B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BBOT revenue for 2026-06-30 was $7.5M. Net income was -$98.6M. Revenue was up 90.0% from 2026-03-31 to 2026-06-30. BBOT currently screens at market cap $610.4M.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
BBOT currently screens at market cap $610.4M. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the BBOT and ZTS stock pages for the full models.
Not investment advice.